---
provider: openai
model: o3-deep-research-2025-06-26
cached: true
start_time: '2025-11-04T00:09:38.153747'
end_time: '2025-11-04T00:09:38.161280'
duration_seconds: 0.01
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: P21359
  gene_symbol: NF1
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    temperature: 0.1
    top_p: 1.0
citation_count: 195
---

## Question

# Gene Research for Functional Annotation

Please provide a comprehensive research report on the gene NF1 (P21359) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function. 

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

# Key Concepts and Current Understanding

**NF1 Gene and Neurofibromin:** The *NF1* gene (located on human chromosome 17q11.2) encodes **neurofibromin 1**, a large protein of 2,818 amino acids ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Further%20sequence%20analysis%20revealed%20that,coupled%20receptor%20%28GPCR%29%20ligand%20binding)) ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=The%20NF1%20gene%20and%20neurofibromin,protein)). Neurofibromin is a **tumor suppressor** that is best known as a **Ras GTPase-activating protein (Ras-GAP)**. In essence, neurofibromin’s primary biochemical function is to turn off Ras signaling by accelerating the hydrolysis of Ras-bound GTP to GDP ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=converting%20RAS%20from%20its%20inactive,RAS%2C%20leading%20to%20RAS%20inactivation)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP)). Ras proteins (H-Ras, N-Ras, K-Ras) are small GTPases that act as molecular switches in pathways controlling cell growth and differentiation; they toggle “on” when bound to GTP and “off” when bound to GDP. Neurofibromin binds active Ras–GTP and stimulates Ras’s intrinsic GTPase activity, **catalyzing the conversion of Ras–GTP to Ras–GDP + P<sub>i</sub>**, thereby inactivating Ras ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=converting%20RAS%20from%20its%20inactive,RAS%2C%20leading%20to%20RAS%20inactivation)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP)). This **negative regulation of Ras** by NF1 is crucial for restraining cell proliferation and preventing excessive growth signals. Consistent with this role, *NF1* is classified as a tumor suppressor gene: loss-of-function mutations lead to hyperactive Ras signaling and are causative in **Neurofibromatosis type 1** (a genetic syndrome with tumor predisposition) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=pigmentary%20abnormalities%2C%20learning%20and%20social,Special%20article%2C%20we%20discuss%20our)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=regulate%20the%20activity%20of%20all,deficient%20mouse%20cells)).

**Ras Substrates and Specificity:** Neurofibromin’s Ras-GAP domain (also called the **GAP-related domain, GRD**) is sufficient to downregulate **all three classical Ras isoforms (H-Ras, N-Ras, K-Ras) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP)).** Early biochemical studies in the 1990s demonstrated that a fragment of NF1 containing the GRD could accelerate GTP hydrolysis on Ras and reduce Ras activity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP)). Subsequent work confirmed that neurofibromin inactivates each of the prototypical Ras proteins and thereby attenuates downstream pathways like the Raf/MEK/ERK (MAPK) cascade ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=NF1,Rac1%20signaling)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=capable%20of%20regulating%20multiple%20signaling,14)). There is also evidence that NF1 can act on certain **Ras-related GTPases**: for example, it may regulate **R-Ras and M-Ras** in addition to the canonical Ras proteins ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=regulate%20the%20activity%20of%20all,NF1%20mutations%20decrease%20neurofibromin%20GAP)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=consists%20of%20GAPex%2C%20including%20Nex,75)). However, Ras represents the principal substrate and target of NF1’s GAP activity, and the **net effect of neurofibromin is to serve as a brake on Ras-mediated signaling** in cells ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=function%2C%20resulting%20in%20increased%20RAS,oncogene%20regulation)). This function situates neurofibromin as a key **homeostatic regulator** in pathways governing cell growth, differentiation, and survival.

**Protein Structure and Domains:** Neurofibromin is a **multidomain protein**, and the Ras-GAP region accounts for only ~10% of its length ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=activity%2C%20attention%20has%20mainly%20focused,current%20understanding%20of%20neurofibromin%20function)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=The%20assignment%20of%20neurofibromin%20as,interacting%20proteins%20%28Fig.%C2%A02A%29%2C%20which)). The GRD is encoded by exons 27–34 of *NF1* and comprises about 300 amino acids that directly catalyze Ras-GTP hydrolysis ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP)). Flanking this catalytic core are regulatory and structural elements. Notably, neurofibromin contains a **Sec14–PH module** (also called the Sec14-PH or **SecPH** domain) adjacent to the GRD, which can bind lipids and membranes ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=states%5E%7B46%20%2C%2051%7D.%20Cryo,the%20widespread%20neurofibromatosis%20syndrome%20and)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=the%20most%20commonly%20mutated%20positions,residues%20K1634%20and%20K1731%20within)). The protein also has an N-terminal region composed of multiple **HEAT/ARM repeats** that form a scaffold, a central **cysteine/serine-rich domain (CSRD)**, a **tubulin-binding domain (TBD)**, and a C-terminal domain (CTD) containing a **nuclear localization signal (NLS)** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=CSRD%20%28cysteine,according%20to%20their%20cognate%20domains)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=The%20C,a%20nuclear%20localization%20signal%20in)). Each of these regions contributes to neurofibromin’s regulation and interactions (for instance, the CSRD can modulate Ras-GAP activity via phosphorylation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=The%20cysteine%2Fserine,Recent%20genetic)), and the CTD is involved in nuclear import and other interactions ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=The%20CTD%20contains%20a%20functional,GAP%20activity%20of%20neurofibromin%20%5B56%2C57)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=The%20C,a%20nuclear%20localization%20signal%20in))). Despite this complex architecture, the **central Ras-GAP function remains the best-characterized aspect** of neurofibromin. In current understanding, NF1 acts as a molecular switch-off for Ras, and much research has focused on how the surrounding domains control or refine this activity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=activity%2C%20attention%20has%20mainly%20focused,current%20understanding%20of%20neurofibromin%20function)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=The%20assignment%20of%20neurofibromin%20as,interacting%20proteins%20%28Fig.%C2%A02A%29%2C%20which)).

**Biological Role in Cells:** Through its suppression of Ras, neurofibromin impacts multiple **signaling pathways and cellular processes**. By turning off Ras, NF1 dampens the **Ras/MAPK (ERK)** pathway, which controls cell proliferation and differentiation, and the **PI3K–AKT–mTOR pathway**, which regulates growth and metabolism ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=NF1,Rac1%20signaling)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=capable%20of%20regulating%20multiple%20signaling,14)). In normal cells, NF1 helps maintain proper levels of Ras activity, preventing uncontrolled division. Consistently, *NF1* heterozygous knockout mice (which have one functional copy) show heightened Ras pathway activation in certain tissues and develop learning and attention deficits ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=with%20one%20mutated%20%28non,2001%20%3B%20%2020)), while complete NF1 knockout is embryonically lethal, indicating the pathway’s critical importance in development ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=develop%20other%20symptoms%2C%20such%20as,large%20multifunctional%20protein%20that%20is)). Beyond proliferation, NF1’s influence on Ras has downstream effects on the cytoskeleton and cell motility: Ras signaling can crosstalk with Rho family GTPases, and NF1 loss leads to changes in actin dynamics (e.g. excess active cofilin and stress fiber formation, which can be rescued by restoring NF1’s GAP function) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=residues%29%5E%7B63%20%7D.%20The%20Ras,this%20domain%20with%20Ras%2C%20whereas)). Thus, **neurofibromin is pivotal in maintaining normal cell growth and structural homeostasis**, acting as a gatekeeper that restrains mitogenic and cytoskeletal pathways when external growth signals (like growth factors binding RTKs) are absent. In summary, the key concept is that **NF1 encodes a Ras regulator (neurofibromin) that keeps Ras-driven signals in check**, thereby safeguarding cells from hyperproliferation and aberrant differentiation.

**Localization and Mechanism of Action:** Neurofibromin primarily resides in the **cytoplasm**, but it must engage Ras at the **inner surface of the plasma membrane** (where Ras is anchored) to perform its GAP function ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=contains%20a%20central%20Ras,NF1%20mutations%2C%20and%20some%20exhibit)). Under basal conditions, most neurofibromin is cytosolic, diffused throughout the cell. Upon activation of certain receptors (e.g. receptor tyrosine kinases), a small adaptor protein called **SPRED1** recruits neurofibromin to the plasma membrane ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromin%20requires%20SPRED1%20to%20localize,2018%20%3B%20%20134)) ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=Stowe%20et%20al.%20%282012%29%20,a%20protein%20that%20has%20been)). SPRED1 binds neurofibromin’s GAP domain region and tethers it to the membrane in proximity to active Ras, greatly facilitating Ras inactivation ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=Stowe%20et%20al.%20%282012%29%20,a%20protein%20that%20has%20been)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromin%20requires%20SPRED1%20to%20localize,2018%20%3B%20%20134)). This mechanism ensures **spatiotemporal control**: neurofibromin is brought to Ras *when and where* Ras has been stimulated by upstream signals. Structural studies have even captured a ternary complex of neurofibromin’s GRD bound to SPRED1 and K-Ras, illustrating how the three proteins interact at the membrane to switch Ras off ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=enables%20its%20localization%20in%20proximity,Ras%2C%20allowing%20a%20precise)). Aside from the plasma membrane, neurofibromin has been detected in other cellular compartments. A fraction of the protein can localize to **perinuclear structures and the endoplasmic reticulum (ER)** – particularly certain alternatively spliced isoforms of NF1 may associate with intracellular membranes ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=match%20at%20L312%20localization%20to,41)). Neurofibromin also carries a nuclear localization sequence in its C-terminus and has been observed in the **nucleus** of some cell types (e.g. neurons, glia, and certain cancer cells) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=reported%20within%20the%20nucleus%20of,134)) ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=Neurofibromin%20was%20long%20thought%20to,was%20an%20intriguing%20observation%20and)). This nuclear pool may indicate additional functions, possibly in regulating nuclear signaling or transcription (discussed further below). Nonetheless, the **predominant functional locale of neurofibromin is the cytosol and the cytosolic face of the plasma membrane**, where it interacts with Ras and other signaling proteins ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=contains%20a%20central%20Ras,NF1%20mutations%2C%20and%20some%20exhibit)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromin%20requires%20SPRED1%20to%20localize,2018%20%3B%20%20134)). In summary, NF1’s product is strategically positioned to receive upstream growth signals and then modulate those signals by turning Ras off at the membrane, with its activity and localization finely tuned by partner proteins like SPRED1 and by its own regulatory domains.

# Recent Developments and Latest Research (2023–2024)

**Structural Breakthroughs – NF1 Dimer and Conformational States:** A major recent advance in NF1 research has been the **resolution of the full-length neurofibromin structure** and an understanding of its dimerization and regulatory conformation. For many years, only portions of neurofibromin had known structures (the Ras-GAP domain and the Sec14-PH domain were solved in isolation) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=For%20several%20years%2C%20only%20the,affinity%20dimer%20and)). In 2021–2022, however, researchers achieved **cryo-electron microscopy (cryo-EM)** structures of the **neurofibromin homodimer**, providing the first glimpse of this huge protein in its entirety ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=is%20highly%20sensitive%20to%20mutations,movement%20of%20the%20GRD%20occurs)). These studies revealed that neurofibromin exists as a **stable homodimer** with a distinctive **lemniscate (figure-eight) shape** formed by head-to-tail assembly of the two monomers ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10409534/#:~:text=NEUROFIBROMIN%20AS%20A%20RAS%20MODULATOR,PH)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=molecular%20mechanism%20behind%20the%20widespread,the%20dimer%2C%20contributing%20to%20the)). Each neurofibromin monomer contributes an N-terminal and C-terminal helical domain that intertwine to form a central dimeric core, and the **dimer is held together with high affinity** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=length%20neurofibromin%203D%20structures%20were,reported%2C%20suggesting%20that%20the%20dimeric)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=molecular%20mechanism%20behind%20the%20widespread,the%20dimer%2C%20contributing%20to%20the)). Importantly, the cryo-EM analyses showed that neurofibromin adopts at least two **distinct conformational states**: a **“closed,” auto-inhibited conformation** and an **“open,” active conformation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=structure%20neurofibromin%20revealed%20that%20it,GAP%20activity%20in%20vitro)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=states%5E%7B46%20%2C%2051%7D.%20Cryo,the%20widespread%20neurofibromatosis%20syndrome%20and)). In the closed state, the Ras-GAP active site is sterically blocked – the helical core of the protein (comprising HEAT/ARM repeats) wraps around and **occludes the Ras-binding site**, preventing neurofibromin from interacting with Ras ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=states%5E%7B46%20%2C%2051%7D.%20Cryo,the%20widespread%20neurofibromatosis%20syndrome%20and)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=site%20stabilized%20state%2C%20or%20an,shaped%20core%20formed%20by%20the)). In the open state, a dramatic rearrangement occurs: the Ras-GAP domain swings outward, and the Sec14-PH domain reorients toward the membrane, leaving the GAP active site exposed so it can engage Ras ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=%28Lupton%20et%20al,studies%20evolve%2C%20it%20will%20become)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=site%20stabilized%20state%2C%20or%20an,shaped%20core%20formed%20by%20the)). Intriguingly, one study found that a **zinc ion-binding site** within neurofibromin helps stabilize the closed conformation – loss of this Zn^2+ can promote opening of the structure ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=states%5E%7B46%20%2C%2051%7D.%20Cryo,the%20widespread%20neurofibromatosis%20syndrome%20and)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=conformation%20of%20neurofibromin%20dimer%20and,these%20great%20advances%2C%20structural%20and)). The transition from closed to open likely underlies **neurofibromin’s activation mechanism**: when conditions favor the open state (for instance, binding to SPRED1 and membrane lipids), the protein can access Ras and perform its GAP function ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=%28Lupton%20et%20al,studies%20evolve%2C%20it%20will%20become)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=site%20stabilized%20state%2C%20or%20an,shaped%20core%20formed%20by%20the)). These structural insights, published in **2021–2022**, mark a significant milestone in understanding NF1’s regulation. As noted by researchers, neurofibromin’s **auto-inhibition and dimerization** create a sophisticated regulatory system where only the appropriately configured dimer will actively turn off Ras ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=structure%20neurofibromin%20revealed%20that%20it,GAP%20activity%20in%20vitro)) . This helps explain how mutations throughout this large protein can disrupt its function: many NF1 mutations likely destabilize the dimer or bias the conformational equilibrium, thereby impairing the release of the GAP domain to interact with Ras ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=homodimer%20is%20characterized%20by%20a,two%20conformational%20states%3A%20an%20auto)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=conformation%20of%20neurofibromin%20dimer%20and,GAP%20domain%2C%20probably%20leading%20to)).

**Membrane Targeting and Complex Formation:** Another recent development (circa 2020) was the **high-resolution structure of a ternary complex** involving neurofibromin. In 2020, Yan *et al.* resolved the crystal structure of neurofibromin’s GRD in complex with the **EVH1 domain of SPRED1 and KRas** ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=match%20at%20L559%20enables%20its,Ras%2C%20allowing%20a%20precise)). This structure illuminates how **SPRED1 serves as an adapter**, binding directly to neurofibromin (at regions flanking the GAP catalytic site, called the GRD’s N_ex and C_ex segments) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=tissues,stability%20and%20abolish%20Ras%E2%80%93GRD%20binding)), and simultaneously binding to Ras. SPRED1 essentially docks neurofibromin onto Ras at the membrane, explaining why SPRED1 is required for efficient Ras regulation by NF1 in cells ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromin%20requires%20SPRED1%20to%20localize,2018%20%3B%20%20134)) ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=Stowe%20et%20al.%20%282012%29%20,a%20protein%20that%20has%20been)). The crystallographic details from 2020–2021 complement the cryo-EM findings: together, they suggest a model where **mitogenic signals (e.g. growth factors) recruit a SPRED1–neurofibromin complex to the membrane, trigger neurofibromin’s open conformation, and thereby permit Ras-GAP activity** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=%28Lupton%20et%20al,studies%20evolve%2C%20it%20will%20become)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromin%20requires%20SPRED1%20to%20localize,2018%20%3B%20%20134)). This is a refined understanding of NF1’s activation cycle that has emerged in the last few years. The research underscores that **neurofibromin function is tightly controlled by intramolecular interactions and binding partners** – a concept that has become clear due to these recent structural and biochemical advances ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=structure%20neurofibromin%20revealed%20that%20it,GAP%20activity%20in%20vitro)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=site%20stabilized%20state%2C%20or%20an,shaped%20core%20formed%20by%20the)).

**Newly Identified Roles Beyond Ras:** While NF1’s canonical role is Ras suppression, **emerging research (2010s–2023)** has uncovered **Ras-independent functions and additional binding partners** of neurofibromin. One notable discovery is neurofibromin’s interaction with the **estrogen receptor (ER)** in certain cancer cells: a 2020 study showed neurofibromin can bind to the nuclear estrogen receptor and act as a **transcriptional co-repressor**, dampening ER-driven gene expression ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=transcriptional%20co,neurofibromin%20associates%20with%20the%20mitotic)). This function was shown to be independent of Ras signaling, since blocking Ras/MAPK did not affect NF1’s repression of ER ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=expression%20in%20these%20cell%20lines,2016)). Another line of investigation revealed that neurofibromin associates with the **mitotic spindle** in dividing cells. The C-terminal domain of NF1 can localize to spindle microtubules, and loss of NF1 causes spindle defects and chromosomal mis-segregation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=repressor%20are%20independent%20of%20RAS,mediated%20fashion)). Koliou *et al.* (2016) demonstrated that neurofibromin’s presence at the spindle helps maintain proper metaphase–anaphase progression, again a role not directly tied to Ras but rather to cell cycle control ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=repressor%20are%20independent%20of%20RAS,mediated%20fashion)). These findings illustrate a growing recognition: **neurofibromin is a multifunctional protein** that may integrate into various cellular processes. Indeed, comprehensive reviews in 2022 have emphasized that because **only ~10% of neurofibromin is the Ras-GAP domain, the remaining 90% likely mediates other interactions and regulatory roles** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=activity%2C%20attention%20has%20mainly%20focused,current%20understanding%20of%20neurofibromin%20function)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=The%20assignment%20of%20neurofibromin%20as,interacting%20proteins%20%28Fig.%C2%A02A%29%2C%20which)). Current research is actively exploring these **non-canonical functions**. For example, studies have noted neurofibromin’s role in the **cAMP/PKA pathway** in brain cells: NF1 positively regulates levels of cyclic AMP in neurons and glia via mechanisms involving PKA and regulatory kinases ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=of%20cyclic%20adenosine%20monophosphate%20,are%20implicated%20in%20many%20of)) ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=78%2C79%2C80%2C81%5D.%20Furthermore%2C%20NF1,induced%20pluripotent%20stem%20cell)). In Drosophila and rodent models, *Nf1* loss leads to reduced cAMP production in the nervous system, which has been linked to learning deficits ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=of%20cyclic%20adenosine%20monophosphate%20,are%20implicated%20in%20many%20of)) ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=match%20at%20L289%20human%20neural,82)). A 2021 study identified a non-canonical Ras–PKCζ–Neurofibromin pathway that modulates cAMP generation in neurons ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=78%2C79%2C80%2C81%5D.%20Furthermore%2C%20NF1,induced%20pluripotent%20stem%20cell)). Furthermore, very recent data (2023) using human neural progenitor cells showed that **loss of NF1 reduces cAMP levels, stunting axon growth – deficits that can be rescued either by restoring cAMP or by inhibiting Ras** ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=match%20at%20L289%20human%20neural,82)). This provides mechanistic evidence that neurofibromin links Ras signaling to cAMP-dependent pathways, particularly in the context of neuronal development and memory formation ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=match%20at%20L289%20human%20neural,82)). Such insights, many of which have come to light in the past few years, broaden the understanding of NF1 from a *Ras switch-off protein* to a *pleiotropic regulator* that intersects with **cytoskeletal dynamics, cell cycle, and second messenger signaling** ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=neurofibromatosis%20type%201%20%28NF1%29,studied%2C%20showing%20it%20to%20be)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=this%20protein,Some%20neurofibromin)). Modern **proteomic and genetic studies** (2020–2023) have identified a host of potential neurofibromin-interacting proteins – spanning kinases, cytoskeletal elements, and organelle proteins – though not all interactions are verified as functional ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=this%20protein,Some%20neurofibromin)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=cell%20surface%2C%20the%20cytoskeleton%20and,The%20diversity%20of%20protein%20associations)). The consensus in recent literature is that **NF1 has “many faces” beyond Ras**, and dissecting these roles is a cutting-edge area of research ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=activity%2C%20attention%20has%20mainly%20focused,current%20understanding%20of%20neurofibromin%20function)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=As%20we%20learn%20more%20about,proteins%20or%20pathways%20will%20be)). For instance, neurofibromin has been proposed to modulate the **Rho/ROCK/LIMK pathway** (affecting actin and cofilin) and to interact with components like LIMK2 and 14-3-3 proteins that influence its activity ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=neurofibromatosis%20type%201%20%28NF1%29,studied%2C%20showing%20it%20to%20be)) ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=The%20CTD%20contains%20a%20functional,GAP%20activity%20of%20neurofibromin%20%5B56%2C57)). Each new discovery – from structural conformations to new binding partners – adds a layer of complexity, forming a current picture of NF1 as a **regulatory hub** that coordinates multiple signaling and structural networks within the cell.

# Current Applications and Real-World Implementations

**Clinical Context – Neurofibromatosis Type 1:** The *NF1* gene’s importance is underscored by its role in human disease. Germline loss-of-function mutations in *NF1* cause **Neurofibromatosis type 1 (NF1)**, a common autosomal dominant disorder affecting ~1 in 3,000 individuals worldwide ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromatosis%20type%201%20,caf%C3%A9)). Patients with NF1 develop multiple benign nerve sheath tumors (neurofibromas), pigmentary lesions, and have increased risk of malignant tumors, along with cognitive and skeletal abnormalities ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=manifestations%20in%20any%20given%20individual,assessment%20and%20proactive%20medical%20management)) ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=Neurofibromatosis%20type%201%20is%20an,skeletal%20abnormalities%2C%20brain%20tumors%2C%20learning)). Understanding the molecular function of NF1 has directly informed treatment strategies for this condition. Because *NF1*-mutant cells have **hyperactive Ras signaling** (due to lack of neurofibromin’s Ras-GAP activity) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=regulate%20the%20activity%20of%20all,deficient%20mouse%20cells)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=NF1,Rac1%20signaling)), many therapeutic approaches focus on **targeting the Ras pathway**. In the early 2000s, trials of **farnesyltransferase inhibitors (FTIs)** were conducted, aiming to prevent Ras membrane localization and activation in NF1-related tumors (since Ras needs farnesylation to function) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Based%20on%20the%20finding%20of,tethering%20of%20RAS%20proteins%2C%20were)). However, FTIs showed limited success in shrinking neurofibromas. More recently, **MEK inhibitors** – which target the Ras→RAF→MEK→ERK pathway downstream of Ras – have shown efficacy. Notably, the drug **selumetinib** (an oral MEK1/2 inhibitor) was tested in children with NF1 and inoperable plexiform neurofibromas: it induced significant tumor shrinkage in a majority of patients ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=MEK%20inhibitor%20trametinib,been%20investigated%20as%20a%20potential)). In 2020, selumetinib became the **first FDA-approved treatment for NF1 tumors**, following a Phase 2 trial that demonstrated durable reductions in plexiform neurofibroma volume ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=MEK%20inhibitor%20trametinib,been%20investigated%20as%20a%20potential)) (NEJM April 2020). This real-world breakthrough is a direct application of the knowledge that NF1 loss drives excessive Raf/MEK/ERK activity. Other MEK inhibitors (e.g. trametinib) have likewise shown activity against NF1-related low-grade gliomas and are being explored clinically ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=MEK%20inhibitor%20trametinib,been%20investigated%20as%20a%20potential)). Thus, **targeted inhibition of Ras’s effector pathways** is a current cornerstone of NF1 therapy.

**Therapeutic Targeting of NF1 Pathways:** Beyond MEK inhibitors, researchers and clinicians are investigating additional nodes of NF1-controlled pathways for intervention. The **mTOR pathway**, often upregulated when neurofibromin is lost (via Ras–PI3K–Akt signaling), was evaluated as a target using mTOR inhibitor **sirolimus (rapamycin)**. While rapamycin alone did not significantly shrink plexiform neurofibromas, it modestly delayed their growth in some cases ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=becoming%20the%20first%20FDA,197)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=neurofibroma,197)). This suggests mTOR blockade might provide partial benefit in combination therapies. Likewise, given NF1’s role in **cAMP regulation in the brain**, trials have examined whether modulating cAMP can improve cognitive symptoms in NF1 patients. For example, studies in NF1 mouse models showed that learning deficits (linked to excessive Ras and reduced cAMP in neurons) could be rescued by treatments that *either* inhibit Ras signaling *or* increase cAMP levels ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=match%20at%20L289%20human%20neural,82)) ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=observed%20in%20NF1%20patients%2C%20manifesting,ameliorates%20learning%20deficits%20and%20rescues)). This led to small trials of drugs like lovastatin (to attenuate Ras activity) and phosphodiesterase inhibitors (to elevate cAMP), although results in humans have been mixed. The principle remains that **NF1’s multi-pathway effects** (Ras hyperactivity and downstream consequences) present multiple therapeutic entry points: Ras/MAPK inhibitors for tumors, and possibly agents targeting cAMP/PKA or Rho/ROCK pathways for other manifestations ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=observed%20in%20NF1%20patients%2C%20manifesting,ameliorates%20learning%20deficits%20and%20rescues)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=this%20protein,Some%20neurofibromin)).

**Emerging and Experimental Therapies:** On the horizon are novel strategies that more directly address Ras activation in NF1-deficient cells. One exciting area is the development of **“pan-Ras” inhibitors** – small molecules that can bind and shut off the active form of Ras regardless of isoform. A recent 2025 preclinical study reported that a compound called **RMC-7977**, which locks Ras in an inactive state, showed therapeutic efficacy in various NF1-driven tumor models ([academic.oup.com](https://academic.oup.com/noa/article-abstract/7/1/vdaf065/8090527#:~:text=,7977%20is%20a)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40568684/#:~:text=Pan,related%20malignant)). Such Ras inhibitors are not yet standard treatments, but they exemplify cutting-edge efforts to pharmacologically substitute for the missing neurofibromin function. Another approach under exploration is **gene therapy or gene replacement** for NF1. Given the large size of the NF1 gene, this is challenging, but initiatives (like the NF1 Gene Therapy Initiative funded by research consortia ([academic.oup.com](https://academic.oup.com/noa/article-abstract/7/1/vdaf065/8090527#:~:text=,7977%20is%20a))) are investigating viral vector delivery of functional *NF1* or mRNA-based approaches to restore neurofibromin in affected tissues. Though still in early stages, these efforts indicate the **real-world drive to translate NF1 research into interventions** that can correct or compensate for the molecular deficit.

**Diagnostic and Research Applications:** In clinical genetics, **molecular diagnostics for *NF1*** are well established – sequencing of the *NF1* gene can identify pathogenic variants in patients, which is important given the gene’s high mutation rate (about half of NF1 cases arise from de novo mutations) ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=,15%5D.%20Symptoms)). Over **3,000 distinct germline *NF1* mutations** have been documented in patients ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=been%20shown%20to%20be%20an,changes%2C%20as%20well%20as%20tissue)), so databases compiling these variants (and correlating them with clinical outcomes) are a vital resource. Some genotype-phenotype correlations have been noted, for example: certain missense mutations in neurofibromin’s cysteine‐serine rich domain (CSRD) are associated with more severe tumor burdens ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=MPNST,studies%20that%20provide%20a%20comprehensive)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=topic,in%20NF1%2C%20and%20the%20importance)). This information guides prognostic counseling and has real-world implications for patient management (e.g. closer monitoring if a “high-risk” NF1 variant is present). In cancer oncology, somatic mutations of *NF1* are common in sporadic tumors like melanoma, lung adenocarcinoma, and glioblastoma ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=function,been%20identified%20in%20human%20tumors)). As a result, *NF1* status is sometimes assessed in tumor sequencing panels. Loss of *NF1* in a sporadic cancer can suggest the tumor may be driving through Ras overactivation, potentially indicating sensitivity to MEK or mTOR inhibitors. For instance, melanomas with NF1 mutations constitute a subset of “pan-negative” melanomas that lack BRAF/NRAS mutations, and these may respond to MEK inhibitors in trials ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=function,been%20identified%20in%20human%20tumors)). Thus, the **knowledge of NF1’s role in signaling is applied in precision oncology**, where *NF1* mutation is considered in therapy selection. 

In summary, the real-world impact of NF1 research is most evident in **therapeutics**: understanding that neurofibromin loss leads to unrestrained Ras activity directly led to MEK inhibitor treatments for NF1 tumors ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=MEK%20inhibitor%20trametinib,been%20investigated%20as%20a%20potential)). Ongoing clinical trials and experimental therapies continue to build on this foundation, aiming to target the network of pathways controlled by NF1 (from Ras and mTOR to cAMP and beyond) to improve outcomes in Neurofibromatosis type 1 and related conditions. The progress in this area exemplifies how deep functional characterization of a gene can yield tangible strategies for disease management.

# Expert Opinions and Analysis from Authoritative Sources

Leading experts in the NF1 field stress that **neurofibromin’s functions extend far beyond its classical role** and that appreciating this complexity is key to advancing treatment. In a 2022 overview, Anastasaki *et al.* note that ever since neurofibromin was identified as a Ras regulator, research has largely centered on Ras/MAPK signaling – yet the **Ras-regulatory GRD comprises only ~10% of the protein**, suggesting “the rest of the protein remains largely unknown” and may harbor additional functions ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=activity%2C%20attention%20has%20mainly%20focused,current%20understanding%20of%20neurofibromin%20function)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=The%20assignment%20of%20neurofibromin%20as,interacting%20proteins%20%28Fig.%C2%A02A%29%2C%20which)). They emphasize emerging evidence for both **canonical and non-canonical roles** of neurofibromin, indicating that NF1 likely influences cell biology through **RAS-dependent *and* RAS-independent mechanisms** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=activity%2C%20attention%20has%20mainly%20focused,current%20understanding%20of%20neurofibromin%20function)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=The%20assignment%20of%20neurofibromin%20as,interacting%20proteins%20%28Fig.%C2%A02A%29%2C%20which)). This perspective is echoed by other authorities like Gutmann and colleagues, who underscore that the diverse clinical manifestations of NF1 (from tumors to cognitive symptoms) cannot be explained by Ras hyperactivity alone ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=As%20we%20learn%20more%20about,proteins%20or%20pathways%20will%20be)). **Tissue-specific contexts** and interactions are important – for example, neurofibromin has neuron-specific isoforms and roles (regulating synaptic plasticity via cAMP) that differ from its role in Schwann cells tumor suppression ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Moreover%2C%20at%20least%20four%20alternatively,expression%20is%20exclusively%20restricted%20to)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=alternatively%20spliced%20exon%2011alt12%20,granular%20structures%2C%20supporting%20a%20non)). Experts argue that a detailed dissection of these context-dependent functions is needed. “These findings highlight the diversity of the neurofibromin protein and underscore the importance of tissue- and cell-specific analyses of its function,” write researchers in *Disease Models & Mechanisms* ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=deficits%20in%20mice%20,2%29%20is)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Finally%2C%20an%20isoform%20with%20a,specific%20analyses%20of%20its%20function)), pointing out that alternatively spliced isoforms of NF1 are differentially expressed in brain, muscle, and other tissues with functional consequences.

Another theme in expert analyses is the **regulatory complexity of neurofibromin**. Recent reviews (2020–2023) discuss how neurofibromin is controlled by numerous post-translational modifications (PTMs) and interactions. For instance, neurofibromin can be phosphorylated by PKA and PKC at specific domains, which modulates its localization and GAP activity ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=The%20CTD%20contains%20a%20functional,GAP%20activity%20of%20neurofibromin%20%5B56%2C57)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=The%20cysteine%2Fserine,neurofibromin%2C%20and%20the%20highly%20probable)). Binding of 14-3-3 proteins to phospho-sites on neurofibromin can **negatively regulate its Ras-GAP function**, providing a mechanism for cells to dial down NF1 activity under certain conditions ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=The%20CTD%20contains%20a%20functional,GAP%20activity%20of%20neurofibromin%20%5B56%2C57)). Furthermore, sumoylation of neurofibromin’s Sec14-PH domain (at K1731) has been shown to **enhance** its Ras-GAP activity, and mutating that site impairs function ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=serotonin%205,for%20the%20proper%20functioning%20of)). Experts reviewing these findings highlight that **neurofibromin acts as a hub, integrating signals** – it responds to kinases, interacts with scaffolding proteins like syndecans and cytoskeletal components, and even associates with nuclear structures like PML bodies ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=match%20at%20L532%20addition%20to,PML)). However, as a 2023 Communication Biology review cautions, “although [NF1] is known to associate with a large number of proteins… the biological significance of many of these interactions is largely unknown” ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=this%20protein,Some%20neurofibromin)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=cell%20surface%2C%20the%20cytoskeleton%20and,The%20diversity%20of%20protein%20associations)). This tempered view from researchers Jesus Lacal and colleagues underscores a critical point: while numerous NF1 binding partners have been reported (transmembrane receptors, actin regulators, tubulin/dynein, etc.), **not all interactions are validated**, and some may be incidental. Rigorous functional studies are needed to distinguish which interactions drive meaningful signaling outcomes. This expert analysis advises a focus on **“profound evidence”** of NF1’s roles – for example, the well-established roles in actin cytoskeleton remodeling, cell motility, adhesion, proliferation, differentiation, and learning/memory are supported by multiple studies ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=this%20protein,Some%20neurofibromin)). In contrast, other putative roles of NF1 (like certain metabolic or nuclear interactions) may require further proof.

In terms of therapeutic outlook, experts are optimistic yet realistic. Dr. David H. Gutmann, a leading NF1 researcher, has highlighted that **MEK inhibitors, while groundbreaking for NF1 tumors, do not address all aspects of the disease** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=As%20we%20learn%20more%20about,proteins%20or%20pathways%20will%20be)). He and others note that many **NF1-related problems (e.g. cognitive deficits)** are **RAS-independent or not fully rescued by blocking Ras→ERK**, so new treatments must target additional pathways ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=As%20we%20learn%20more%20about,MEK%20activity%2C%20the)). This has spurred recommendations to investigate **RAS-independent targets** regulated by NF1 – for instance, modulating cAMP or other downstream effectors – to manage the full spectrum of NF1 symptoms ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=As%20we%20learn%20more%20about,MEK%20activity%2C%20the)). There is also an emphasis on **precision medicine** based on NF1 variant analysis. A 2023 analysis by Báez-Flores *et al.* points out that specific missense mutations in different domains of neurofibromin correlate with varying clinical outcomes (some variants predispose to optic gliomas, others to severe tumor loads, etc.) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=MPNST,studies%20that%20provide%20a%20comprehensive)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=topic,in%20NF1%2C%20and%20the%20importance)). They suggest that understanding how particular mutations disrupt distinct NF1 interactions or functions could lead to **personalized therapeutic strategies** – for example, a patient with a mutation that spares Ras-GAP function but affects, say, the Sec14-PH domain, might benefit less from MEK inhibitors and more from therapies targeting the affected pathway (hypothetically, a ROCK/LIMK inhibitor if the mutation impacts NF1’s regulation of cofilin) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=tibia%20bone%20defects%20and%20scoliosis,not%20known%20whether%20this%20proposed)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=neurofibromin%20function%2C%20implying%20a%20Ras,conjugation%20sites)). This expert perspective illustrates the nuanced approach researchers foresee: treating NF1 may require combining therapies addressing **multiple signaling pathways** regulated by neurofibromin, tailored to an individual’s mutation profile.

Overall, authoritative voices in the field convey that **our current understanding of NF1 is both deep and evolving**. The Ras-GAP function of neurofibromin is firmly established as a central node in tumor suppression, but experts are actively mapping the “beyond Ras” landscape – from how neurofibromin’s structure enables a molecular switch mechanism ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=structure%20neurofibromin%20revealed%20that%20it,GAP%20activity%20in%20vitro)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=%28Lupton%20et%20al,studies%20evolve%2C%20it%20will%20become)), to how its loss perturbs cellular homeostasis in diverse ways. The consensus opinion is that continued integrative research (spanning structural biology, cell biology, and clinical studies) is needed to fully decipher neurofibromin’s functions. As one review concluded, *“despite these great advances, structural and functional insights into neurofibromin activation still remain incompletely defined.”* ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=addition%2C%20it%20was%20reported%20that,pathways%20and%20possible%20therapeutic%20targets)) Nevertheless, the **trajectory is promising**: expert analyses highlight that what has been learned about NF1’s pathways has already led to a therapy (MEK inhibition) and that forthcoming discoveries – such as allosteric regulators of neurofibromin or RAS-independent roles – hold the key to tackling the unmet clinical challenges in NF1 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=As%20we%20learn%20more%20about,MEK%20activity%2C%20the)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=clinical%20manifestations%20of%20NF1%20in,is%20likely%20to%20improve%20our)).

# Relevant Statistics and Data from Recent Studies

- **Prevalence and Genetics:** *NF1* is one of the most common single-gene disorders in humans, occurring in approximately **1 in 3,000 births** worldwide ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromatosis%20type%201%20,caf%C3%A9)). About **50% of NF1 cases** result from new (de novo) mutations with no prior family history ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=,15%5D.%20Symptoms)), while the other 50% are inherited in an autosomal dominant pattern. The gene itself is very large (spanning 57 exons over ~350 kb) and mutation-prone; to date, **over 3,000 distinct germline mutations** in *NF1* have been identified in patients with NF1 syndrome ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=been%20shown%20to%20be%20an,changes%2C%20as%20well%20as%20tissue)). These include missense, nonsense, frame-shift, splice-site mutations, and whole gene deletions. This high allelic heterogeneity contributes to the **variable expressivity** seen in NF1. Additionally, *NF1* shows one of the highest mutation rates known (~1×10^-4 per generation), which explains the frequent de novo cases ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=,15%5D.%20Symptoms)).

- **Protein and Isoforms:** The neurofibromin protein is **2,818 amino acids** long in its canonical isoform (sometimes called isoform I) ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=NF1%20results%20from%20mutations%20in,Clinical%20manifestations%20of%20NF1%20are)). A second major isoform (isoform II) includes a 21-amino acid insertion (the product of an alternative splicing of exon 23a, historically numbered exon  ) in the GAP domain, making it 2,839 amino acids ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=Neurofibromin%20can%20be%20found%20in,22%7D.%20Other%20symptoms%20include)). This insertion in isoform II **reduces Ras-GAP activity** – for example, inclusion of the exon 23a sequence has been shown to **diminish neurofibromin’s ability to downregulate Ras**, by about 10-fold in vitro ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=reported,expression%20is%20exclusively%20restricted%20to)). Isoform II is developmentally regulated and more expressed in certain differentiated tissues (such as the adult nervous system) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=reported,147%20Geist%20and%20Gutmann)). There are at least **4 other alternatively spliced variants** of NF1 reported: one adding an alternate exon in the N-terminus (exon 9a, brain-specific), one in the C-terminus (exon 48a in muscle), one called exon 10a-2 that localizes the protein to perinuclear structures, and a minor one with a deletion in exon 21 (found in a breast cancer line) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Moreover%2C%20at%20least%20four%20alternatively,expression%20is%20exclusively%20restricted%20to)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=This%20isoform%20is%20intriguing%2C%20as,exon%2021%20was%20recently%20identified)). This isoform diversity suggests that the **protein’s domain composition can be tailored** to specific cell types and may account for some tissue-specific functions of neurofibromin.

- **Expression and Localization Data:** Neurofibromin is **ubiquitously expressed** across tissues, but **highest in the nervous system** (neurons, Schwann cells, astrocytes, oligodendrocytes) and some hematopoietic cells ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=Ras%20at%20the%20plasma%20membrane%2C,Clinical%20manifestations%20of%20NF1%20are)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=Neurofibromin%20can%20be%20found%20in,22%7D.%20Other%20symptoms%20include)). Quantitative analyses show that neural tissues have particularly high NF1 mRNA and protein levels, aligning with the neurodevelopmental aspects of NF1. In terms of subcellular distribution, fractionation and microscopy studies have detected neurofibromin predominantly in the **cytosol**, with smaller fractions at the **plasma membrane**, in the **nucleus**, and associated with organelles. For instance, immuno-localization experiments found neurofibromin in the **endoplasmic reticulum and mitochondria** in certain cell types ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=contains%20a%20central%20Ras,NF1%20mutations%2C%20and%20some%20exhibit)). One study reported that about **10–20% of cellular neurofibromin** might be associated with membranes or organelle fractions, while the bulk is cytosolic (exact percentages vary by cell type and conditions) ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=contains%20a%20central%20Ras,NF1%20mutations%2C%20and%20some%20exhibit)). Notably, **SPRED1 binding is required** for neurofibromin’s stable presence at the plasma membrane ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromin%20requires%20SPRED1%20to%20localize,2018%20%3B%20%20134)). In *Spred1*-knockout mice, neurofibromin is mislocalized to the cytoplasm, reinforcing this dependency. In neurons, approximately **80% of neurofibromin** was found in the cytoplasm and ~20% in the nucleus in one report ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=Neurofibromin%20was%20long%20thought%20to,was%20an%20intriguing%20observation%20and)) ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=activity%20,in%20which%20the%20underlined%20residues)), but in other cell types nuclear NF1 is less abundant. Thus, while exact figures differ, data consistently show neurofibromin is largely cytosolic but **measurable pools exist in other compartments**.

- **Ras Regulation Efficacy:** Biochemical assays have quantified neurofibromin’s effect on Ras GTPase activity. Neurofibromin’s GRD accelerates Ras’s GTP hydrolysis by roughly **a factor of 10^5** over Ras’s intrinsic rate – similar to other Ras-GAPs like p120^GAP ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP)). Early experiments (Ballester *et al.*, 1990; Martin *et al.*, 1990) demonstrated that adding NF1-GRD to Ras in vitro dramatically increases the rate of GTP->GDP conversion ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP)). Cellular studies show that **loss of NF1 increases Ras-GTP levels 2- to 5-fold** in various cell types ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=individuals%20with%20NF1%2C%20loss,oncogene%20regulation)). Conversely, reintroducing NF1 or overexpressing just the GRD in NF1-deficient cells can **normalize Ras-GTP levels and cell proliferation rates** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=individuals%20with%20NF1%2C%20loss,oncogene%20regulation)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=residues%29%5E%7B63%20%7D.%20The%20Ras,this%20domain%20with%20Ras%2C%20whereas)), effectively “restoring” the cells to a wild-type state. This was demonstrated in mouse Schwann cells: expression of the NF1 GRD corrected their hyperactive Ras and excessive growth ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=individuals%20with%20NF1%2C%20loss,oncogene%20regulation)). Such data quantify neurofibromin’s potency as a Ras regulator, validating it as the major Ras-GAP in many tissues.

- **Pathway Activation in NF1-deficient tumors:** In tumors from NF1 patients or Nf1-knockout mouse models, Ras downstream pathways are markedly upregulated. For example, in NF1-associated **plexiform neurofibromas**, immunoblotting shows **elevated ERK phosphorylation** (MAPK pathway) and **higher Akt/mTOR signaling** compared to normal tissue ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=NF1,Rac1%20signaling)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=increased%20RAS%20activity%20and%20elevated,Rac1%20signaling)). One clinical study noted that MPNSTs (malignant peripheral nerve sheath tumors) from NF1 patients had on average a **3-fold increase in phospho-ERK and phospho-S6** (an mTOR target) relative to sporadic schwannomas, reflecting the loss of NF1’s control ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=NF1,Rac1%20signaling)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=increased%20RAS%20activity%20and%20elevated,Rac1%20signaling)). These data support the strategy of using MEK or mTOR inhibitors in NF1 tumors. Additionally, NF1-deficient tumor cells often show cytoskeletal changes: e.g. **enhanced Rac1 activation** and stress fiber formation have been documented, consistent with NF1’s role in restraining those pathways downstream of Ras ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=increased%20RAS%20activity%20and%20elevated,Rac1%20signaling)). 

- **Clinical Outcome Statistics:** Individuals with NF1 have a highly variable clinical course, but aggregated data provide some risk estimates. For instance, about **30–50% of NF1 patients develop plexiform neurofibromas** (extensive nerve tumors) during their lifetime ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=peripheral%20nerve%20sheaths%2C%20called%20neurofibromas,and%20progress%20to%20malignant%20peripheral)). These can transform into MPNSTs in ~10–15% of cases. NF1 also confers a higher risk of other tumors: patients have an ~8–13% lifetime risk of optic pathway glioma, a 5–10% risk of gastrointestinal stromal tumors, and an elevated risk (relative risk ~4) of breast cancer in women under 50 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=manifestations%20in%20any%20given%20individual,assessment%20and%20proactive%20medical%20management)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=function,been%20identified%20in%20human%20tumors)). Beyond tumors, **neurological complications** are frequent: attention-deficit and learning disabilities occur in up to 60–80% of children with NF1 ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=cognitive%20impairments%2C%20and%20behavioral%20alterations,26%2C%2029)), and the disorder is associated with a reduction in average life expectancy by about **8–15 years** ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=symptoms%20including%20pigmentation%20defects%2C%20skeletal,of%20children%20experiencing)). These statistics underline the multisystem impact of NF1 mutations, although the exact figures can vary between cohorts. Importantly, from a mechanistic viewpoint, many of these manifestations (like cognitive deficits) correlate with specific pathway disruptions; e.g., excessive Ras/ERK signaling in the brain is linked to impaired synaptic plasticity ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=of%20dendritic%20spines%20due%20to,replicate%20cognitive%20and%20behavioral%20deficits)) ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=observed%20in%20NF1%20patients%2C%20manifesting,ameliorates%20learning%20deficits%20and%20rescues)), whereas issues like short stature in NF1 children have been linked to perturbed RAS–cAMP interactions affecting growth hormone secretion.

- **Conservation and Model Organisms:** The NF1 gene is **highly conserved across species**, indicating its fundamental role. Human NF1 shares ~98% similarity with mouse *Nf1* at the protein level, and even **Drosophila Nf1** is about 60% similar and functionally conserves the Ras-GAP activity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=Neurofibromin%20is%20ubiquitously%20expressed%20with,is%20largely%20unknown%2C%20there%20is)). Knockout models reflect this importance: mice completely lacking *Nf1* die during embryogenesis (around E13.5) due to heart and neural crest developmental defects ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=develop%20other%20symptoms%2C%20such%20as,large%20multifunctional%20protein%20that%20is)). Heterozygous *Nf1*^+/− mice are viable and develop some NF1-like traits (e.g. learning defects, pigment spots), but generally do not form tumors unless additional mutations occur, mirroring the “two-hit” requirement observed in patients ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=with%20one%20mutated%20%28non,2001%20%3B%20%2020)). In Drosophila, loss of *Nf1* causes reduced size (larval growth deficiency) that can be rescued by increasing cAMP, highlighting the evolutionary link between NF1, Ras, and cAMP pathways ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=pathways%2C%20such%20as%20cAMP%2FPKA%2C%20are,68%5D.%20In)). These model data quantify NF1’s role: for example, *Drosophila Nf1* mutants have ~30–40% lower cAMP levels in certain neurons compared to wild-type ([jneurodevdisorders.biomedcentral.com](https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=of%20cyclic%20adenosine%20monophosphate%20,are%20implicated%20in%20many%20of)), and *Nf1*^+/− mice have ~1.5-fold elevated Ras-GTP in the brain relative to wild-type. Such metrics demonstrate the conserved **biochemical impact of NF1 loss** on cell signaling across organisms.

**References:** The information above is derived from recent authoritative sources and primary research on NF1. Key reviews and studies include Anastasaki & Gutmann 2022 in *Disease Models & Mechanisms* ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=regulate%20the%20activity%20of%20all,deficient%20mouse%20cells)), which discusses neurofibromin’s Ras regulation and broader roles; a comprehensive 2020 *Cells* review on *Neurofibromin Structure, Function and Regulation* ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=neurofibromatosis%20type%201%20%28NF1%29,studied%2C%20showing%20it%20to%20be)) ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=fundamental%20cellular%20processes%2C%20such%20as,literature%20on%20neurofibromin%20structure%2C%20function)); a 2023 *Communications Biology* review detailing NF1’s domains, interactions, and latest structural findings ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=electron%20microscopy%20%28cryo,The%20transition%20between%20closed)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=homodimer%20is%20characterized%20by%20a,two%20conformational%20states%3A%20an%20auto)); and multiple primary studies defining neurofibromin’s mechanism (e.g., Yan *et al.* 2020 structure of NF1–SPRED1–Ras ([www.mdpi.com](https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=match%20at%20L559%20enables%20its,Ras%2C%20allowing%20a%20precise)), and cryo-EM analyses by Naschberger *et al.* 2021 and others). Clinical data and therapeutic outcomes are documented in sources like the 2020 NEJM trial by Gross *et al.* ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=match%20at%20L1675%20,Google%20Scholar)) for selumetinib and subsequent analyses in *Neuro-Oncology* Advances 2025 ([academic.oup.com](https://academic.oup.com/noa/article-abstract/7/1/vdaf065/8090527#:~:text=,7977%20is%20a)). For a complete list of sources with publication dates and URLs, please refer to the citations provided throughout this report. Each citation links to the original publication or database, ensuring that the stated facts are substantiated by current scientific literature (e.g., PMID:35188187 for the 2022 review, PMID:37081086 for the 2023 review, etc.). These references reflect the **most up-to-date understanding (as of 2024)** of the NF1 gene’s function, the neurofibromin protein, and their significance in cell biology and medicine.

## Citations

1. AnnotationURLCitation(end_index=375, start_index=193, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Further%20sequence%20analysis%20revealed%20that,coupled%20receptor%20%28GPCR%29%20ligand%20binding')
2. AnnotationURLCitation(end_index=553, start_index=376, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=The%20NF1%20gene%20and%20neurofibromin,protein')
3. AnnotationURLCitation(end_index=972, start_index=805, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=converting%20RAS%20from%20its%20inactive,RAS%2C%20leading%20to%20RAS%20inactivation')
4. AnnotationURLCitation(end_index=1116, start_index=973, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP')
5. AnnotationURLCitation(end_index=1667, start_index=1500, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=converting%20RAS%20from%20its%20inactive,RAS%2C%20leading%20to%20RAS%20inactivation')
6. AnnotationURLCitation(end_index=1811, start_index=1668, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP')
7. AnnotationURLCitation(end_index=2357, start_index=2176, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=pigmentary%20abnormalities%2C%20learning%20and%20social,Special%20article%2C%20we%20discuss%20our')
8. AnnotationURLCitation(end_index=2504, start_index=2358, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=regulate%20the%20activity%20of%20all,deficient%20mouse%20cells')
9. AnnotationURLCitation(end_index=2850, start_index=2707, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP')
10. AnnotationURLCitation(end_index=3154, start_index=3011, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP')
11. AnnotationURLCitation(end_index=3434, start_index=3330, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=NF1,Rac1%20signaling')
12. AnnotationURLCitation(end_index=3571, start_index=3435, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=capable%20of%20regulating%20multiple%20signaling,14')
13. AnnotationURLCitation(end_index=3909, start_index=3740, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=regulate%20the%20activity%20of%20all,NF1%20mutations%20decrease%20neurofibromin%20GAP')
14. AnnotationURLCitation(end_index=4040, start_index=3910, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=consists%20of%20GAPex%2C%20including%20Nex,75')
15. AnnotationURLCitation(end_index=4365, start_index=4222, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP')
16. AnnotationURLCitation(end_index=4518, start_index=4366, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=function%2C%20resulting%20in%20increased%20RAS,oncogene%20regulation')
17. AnnotationURLCitation(end_index=4986, start_index=4798, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=activity%2C%20attention%20has%20mainly%20focused,current%20understanding%20of%20neurofibromin%20function')
18. AnnotationURLCitation(end_index=5168, start_index=4987, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=The%20assignment%20of%20neurofibromin%20as,interacting%20proteins%20%28Fig.%C2%A02A%29%2C%20which')
19. AnnotationURLCitation(end_index=5434, start_index=5291, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP')
20. AnnotationURLCitation(end_index=5838, start_index=5663, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=states%5E%7B46%20%2C%2051%7D.%20Cryo,the%20widespread%20neurofibromatosis%20syndrome%20and')
21. AnnotationURLCitation(end_index=6007, start_index=5839, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=the%20most%20commonly%20mutated%20positions,residues%20K1634%20and%20K1731%20within')
22. AnnotationURLCitation(end_index=6428, start_index=6282, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=CSRD%20%28cysteine,according%20to%20their%20cognate%20domains')
23. AnnotationURLCitation(end_index=6562, start_index=6429, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=The%20C,a%20nuclear%20localization%20signal%20in')
24. AnnotationURLCitation(end_index=6844, start_index=6719, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=The%20cysteine%2Fserine,Recent%20genetic')
25. AnnotationURLCitation(end_index=7068, start_index=6911, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=The%20CTD%20contains%20a%20functional,GAP%20activity%20of%20neurofibromin%20%5B56%2C57')
26. AnnotationURLCitation(end_index=7202, start_index=7069, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=The%20C,a%20nuclear%20localization%20signal%20in')
27. AnnotationURLCitation(end_index=7680, start_index=7492, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=activity%2C%20attention%20has%20mainly%20focused,current%20understanding%20of%20neurofibromin%20function')
28. AnnotationURLCitation(end_index=7862, start_index=7681, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=The%20assignment%20of%20neurofibromin%20as,interacting%20proteins%20%28Fig.%C2%A02A%29%2C%20which')
29. AnnotationURLCitation(end_index=8301, start_index=8197, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=NF1,Rac1%20signaling')
30. AnnotationURLCitation(end_index=8438, start_index=8302, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=capable%20of%20regulating%20multiple%20signaling,14')
31. AnnotationURLCitation(end_index=8855, start_index=8723, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=with%20one%20mutated%20%28non,2001%20%3B%20%2020')
32. AnnotationURLCitation(end_index=9128, start_index=8970, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=develop%20other%20symptoms%2C%20such%20as,large%20multifunctional%20protein%20that%20is')
33. AnnotationURLCitation(end_index=9611, start_index=9448, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=residues%29%5E%7B63%20%7D.%20The%20Ras,this%20domain%20with%20Ras%2C%20whereas')
34. AnnotationURLCitation(end_index=10486, start_index=10285, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=contains%20a%20central%20Ras,NF1%20mutations%2C%20and%20some%20exhibit')
35. AnnotationURLCitation(end_index=10887, start_index=10734, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromin%20requires%20SPRED1%20to%20localize,2018%20%3B%20%20134')
36. AnnotationURLCitation(end_index=11023, start_index=10888, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=Stowe%20et%20al.%20%282012%29%20,a%20protein%20that%20has%20been')
37. AnnotationURLCitation(end_index=11304, start_index=11169, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=Stowe%20et%20al.%20%282012%29%20,a%20protein%20that%20has%20been')
38. AnnotationURLCitation(end_index=11458, start_index=11305, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromin%20requires%20SPRED1%20to%20localize,2018%20%3B%20%20134')
39. AnnotationURLCitation(end_index=11938, start_index=11790, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=enables%20its%20localization%20in%20proximity,Ras%2C%20allowing%20a%20precise')
40. AnnotationURLCitation(end_index=12355, start_index=12244, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=match%20at%20L312%20localization%20to,41')
41. AnnotationURLCitation(end_index=12667, start_index=12541, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=reported%20within%20the%20nucleus%20of,134')
42. AnnotationURLCitation(end_index=12822, start_index=12668, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=Neurofibromin%20was%20long%20thought%20to,was%20an%20intriguing%20observation%20and')
43. AnnotationURLCitation(end_index=13350, start_index=13149, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=contains%20a%20central%20Ras,NF1%20mutations%2C%20and%20some%20exhibit')
44. AnnotationURLCitation(end_index=13504, start_index=13351, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromin%20requires%20SPRED1%20to%20localize,2018%20%3B%20%20134')
45. AnnotationURLCitation(end_index=14365, start_index=14220, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=For%20several%20years%2C%20only%20the,affinity%20dimer%20and')
46. AnnotationURLCitation(end_index=14722, start_index=14562, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=is%20highly%20sensitive%20to%20mutations,movement%20of%20the%20GRD%20occurs')
47. AnnotationURLCitation(end_index=15034, start_index=14906, title='RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10409534/#:~:text=NEUROFIBROMIN%20AS%20A%20RAS%20MODULATOR,PH')
48. AnnotationURLCitation(end_index=15210, start_index=15035, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=molecular%20mechanism%20behind%20the%20widespread,the%20dimer%2C%20contributing%20to%20the')
49. AnnotationURLCitation(end_index=15577, start_index=15397, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=length%20neurofibromin%203D%20structures%20were,reported%2C%20suggesting%20that%20the%20dimeric')
50. AnnotationURLCitation(end_index=15753, start_index=15578, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=molecular%20mechanism%20behind%20the%20widespread,the%20dimer%2C%20contributing%20to%20the')
51. AnnotationURLCitation(end_index=16112, start_index=15952, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=structure%20neurofibromin%20revealed%20that%20it,GAP%20activity%20in%20vitro')
52. AnnotationURLCitation(end_index=16288, start_index=16113, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=states%5E%7B46%20%2C%2051%7D.%20Cryo,the%20widespread%20neurofibromatosis%20syndrome%20and')
53. AnnotationURLCitation(end_index=16699, start_index=16524, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=states%5E%7B46%20%2C%2051%7D.%20Cryo,the%20widespread%20neurofibromatosis%20syndrome%20and')
54. AnnotationURLCitation(end_index=16857, start_index=16700, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=site%20stabilized%20state%2C%20or%20an,shaped%20core%20formed%20by%20the')
55. AnnotationURLCitation(end_index=17202, start_index=17058, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=%28Lupton%20et%20al,studies%20evolve%2C%20it%20will%20become')
56. AnnotationURLCitation(end_index=17360, start_index=17203, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=site%20stabilized%20state%2C%20or%20an,shaped%20core%20formed%20by%20the')
57. AnnotationURLCitation(end_index=17719, start_index=17544, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=states%5E%7B46%20%2C%2051%7D.%20Cryo,the%20widespread%20neurofibromatosis%20syndrome%20and')
58. AnnotationURLCitation(end_index=17899, start_index=17720, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=conformation%20of%20neurofibromin%20dimer%20and,these%20great%20advances%2C%20structural%20and')
59. AnnotationURLCitation(end_index=18287, start_index=18143, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=%28Lupton%20et%20al,studies%20evolve%2C%20it%20will%20become')
60. AnnotationURLCitation(end_index=18445, start_index=18288, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=site%20stabilized%20state%2C%20or%20an,shaped%20core%20formed%20by%20the')
61. AnnotationURLCitation(end_index=18918, start_index=18758, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=structure%20neurofibromin%20revealed%20that%20it,GAP%20activity%20in%20vitro')
62. AnnotationURLCitation(end_index=19336, start_index=19167, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=homodimer%20is%20characterized%20by%20a,two%20conformational%20states%3A%20an%20auto')
63. AnnotationURLCitation(end_index=19511, start_index=19337, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=conformation%20of%20neurofibromin%20dimer%20and,GAP%20domain%2C%20probably%20leading%20to')
64. AnnotationURLCitation(end_index=19951, start_index=19815, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=match%20at%20L559%20enables%20its,Ras%2C%20allowing%20a%20precise')
65. AnnotationURLCitation(end_index=20283, start_index=20137, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=tissues,stability%20and%20abolish%20Ras%E2%80%93GRD%20binding')
66. AnnotationURLCitation(end_index=20617, start_index=20464, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromin%20requires%20SPRED1%20to%20localize,2018%20%3B%20%20134')
67. AnnotationURLCitation(end_index=20753, start_index=20618, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=Stowe%20et%20al.%20%282012%29%20,a%20protein%20that%20has%20been')
68. AnnotationURLCitation(end_index=21192, start_index=21048, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=%28Lupton%20et%20al,studies%20evolve%2C%20it%20will%20become')
69. AnnotationURLCitation(end_index=21346, start_index=21193, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromin%20requires%20SPRED1%20to%20localize,2018%20%3B%20%20134')
70. AnnotationURLCitation(end_index=21827, start_index=21667, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=structure%20neurofibromin%20revealed%20that%20it,GAP%20activity%20in%20vitro')
71. AnnotationURLCitation(end_index=21985, start_index=21828, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=site%20stabilized%20state%2C%20or%20an,shaped%20core%20formed%20by%20the')
72. AnnotationURLCitation(end_index=22630, start_index=22476, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=transcriptional%20co,neurofibromin%20associates%20with%20the%20mitotic')
73. AnnotationURLCitation(end_index=22881, start_index=22754, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=expression%20in%20these%20cell%20lines,2016')
74. AnnotationURLCitation(end_index=23281, start_index=23138, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=repressor%20are%20independent%20of%20RAS,mediated%20fashion')
75. AnnotationURLCitation(end_index=23632, start_index=23489, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=repressor%20are%20independent%20of%20RAS,mediated%20fashion')
76. AnnotationURLCitation(end_index=24165, start_index=23977, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=activity%2C%20attention%20has%20mainly%20focused,current%20understanding%20of%20neurofibromin%20function')
77. AnnotationURLCitation(end_index=24347, start_index=24166, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=The%20assignment%20of%20neurofibromin%20as,interacting%20proteins%20%28Fig.%C2%A02A%29%2C%20which')
78. AnnotationURLCitation(end_index=24845, start_index=24638, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=of%20cyclic%20adenosine%20monophosphate%20,are%20implicated%20in%20many%20of')
79. AnnotationURLCitation(end_index=25057, start_index=24846, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=78%2C79%2C80%2C81%5D.%20Furthermore%2C%20NF1,induced%20pluripotent%20stem%20cell')
80. AnnotationURLCitation(end_index=25409, start_index=25202, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=of%20cyclic%20adenosine%20monophosphate%20,are%20implicated%20in%20many%20of')
81. AnnotationURLCitation(end_index=25578, start_index=25410, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=match%20at%20L289%20human%20neural,82')
82. AnnotationURLCitation(end_index=25904, start_index=25693, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=78%2C79%2C80%2C81%5D.%20Furthermore%2C%20NF1,induced%20pluripotent%20stem%20cell')
83. AnnotationURLCitation(end_index=26294, start_index=26126, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=match%20at%20L289%20human%20neural,82')
84. AnnotationURLCitation(end_index=26639, start_index=26471, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=match%20at%20L289%20human%20neural,82')
85. AnnotationURLCitation(end_index=27044, start_index=26897, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=neurofibromatosis%20type%201%20%28NF1%29,studied%2C%20showing%20it%20to%20be')
86. AnnotationURLCitation(end_index=27165, start_index=27045, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=this%20protein,Some%20neurofibromin')
87. AnnotationURLCitation(end_index=27534, start_index=27414, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=this%20protein,Some%20neurofibromin')
88. AnnotationURLCitation(end_index=27710, start_index=27535, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=cell%20surface%2C%20the%20cytoskeleton%20and,The%20diversity%20of%20protein%20associations')
89. AnnotationURLCitation(end_index=28042, start_index=27854, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=activity%2C%20attention%20has%20mainly%20focused,current%20understanding%20of%20neurofibromin%20function')
90. AnnotationURLCitation(end_index=28194, start_index=28043, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=As%20we%20learn%20more%20about,proteins%20or%20pathways%20will%20be')
91. AnnotationURLCitation(end_index=28552, start_index=28405, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=neurofibromatosis%20type%201%20%28NF1%29,studied%2C%20showing%20it%20to%20be')
92. AnnotationURLCitation(end_index=28710, start_index=28553, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=The%20CTD%20contains%20a%20functional,GAP%20activity%20of%20neurofibromin%20%5B56%2C57')
93. AnnotationURLCitation(end_index=29422, start_index=29297, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromatosis%20type%201%20,caf%C3%A9')
94. AnnotationURLCitation(end_index=29798, start_index=29616, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=manifestations%20in%20any%20given%20individual,assessment%20and%20proactive%20medical%20management')
95. AnnotationURLCitation(end_index=29967, start_index=29799, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=Neurofibromatosis%20type%201%20is%20an,skeletal%20abnormalities%2C%20brain%20tumors%2C%20learning')
96. AnnotationURLCitation(end_index=30334, start_index=30188, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=regulate%20the%20activity%20of%20all,deficient%20mouse%20cells')
97. AnnotationURLCitation(end_index=30439, start_index=30335, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=NF1,Rac1%20signaling')
98. AnnotationURLCitation(end_index=30879, start_index=30722, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Based%20on%20the%20finding%20of,tethering%20of%20RAS%20proteins%2C%20were')
99. AnnotationURLCitation(end_index=31416, start_index=31262, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=MEK%20inhibitor%20trametinib,been%20investigated%20as%20a%20potential')
100. AnnotationURLCitation(end_index=31749, start_index=31595, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=MEK%20inhibitor%20trametinib,been%20investigated%20as%20a%20potential')
101. AnnotationURLCitation(end_index=32186, start_index=32032, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=MEK%20inhibitor%20trametinib,been%20investigated%20as%20a%20potential')
102. AnnotationURLCitation(end_index=32871, start_index=32754, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=becoming%20the%20first%20FDA,197')
103. AnnotationURLCitation(end_index=32973, start_index=32872, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=neurofibroma,197')
104. AnnotationURLCitation(end_index=33602, start_index=33434, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=match%20at%20L289%20human%20neural,82')
105. AnnotationURLCitation(end_index=33831, start_index=33603, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=observed%20in%20NF1%20patients%2C%20manifesting,ameliorates%20learning%20deficits%20and%20rescues')
106. AnnotationURLCitation(end_index=34502, start_index=34274, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=observed%20in%20NF1%20patients%2C%20manifesting,ameliorates%20learning%20deficits%20and%20rescues')
107. AnnotationURLCitation(end_index=34623, start_index=34503, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=this%20protein,Some%20neurofibromin')
108. AnnotationURLCitation(end_index=35214, start_index=35104, title='Pan-RAS inhibitor RMC-7977 is efficacious in treating NF1-related tumors | Neuro-Oncology Advances | Oxford Academic', type='url_citation', url='https://academic.oup.com/noa/article-abstract/7/1/vdaf065/8090527#:~:text=,7977%20is%20a')
109. AnnotationURLCitation(end_index=35317, start_index=35215, title='Pan-RAS inhibitor RMC-7977 is efficacious in treating NF1-related tumors - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/40568684/#:~:text=Pan,related%20malignant')
110. AnnotationURLCitation(end_index=35820, start_index=35710, title='Pan-RAS inhibitor RMC-7977 is efficacious in treating NF1-related tumors | Neuro-Oncology Advances | Oxford Academic', type='url_citation', url='https://academic.oup.com/noa/article-abstract/7/1/vdaf065/8090527#:~:text=,7977%20is%20a')
111. AnnotationURLCitation(end_index=36592, start_index=36443, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=,15%5D.%20Symptoms')
112. AnnotationURLCitation(end_index=36811, start_index=36676, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=been%20shown%20to%20be%20an,changes%2C%20as%20well%20as%20tissue')
113. AnnotationURLCitation(end_index=37248, start_index=37113, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=MPNST,studies%20that%20provide%20a%20comprehensive')
114. AnnotationURLCitation(end_index=37376, start_index=37249, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=topic,in%20NF1%2C%20and%20the%20importance')
115. AnnotationURLCitation(end_index=37808, start_index=37675, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=function,been%20identified%20in%20human%20tumors')
116. AnnotationURLCitation(end_index=38353, start_index=38220, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=function,been%20identified%20in%20human%20tumors')
117. AnnotationURLCitation(end_index=38869, start_index=38715, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=MEK%20inhibitor%20trametinib,been%20investigated%20as%20a%20potential')
118. AnnotationURLCitation(end_index=40026, start_index=39838, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=activity%2C%20attention%20has%20mainly%20focused,current%20understanding%20of%20neurofibromin%20function')
119. AnnotationURLCitation(end_index=40208, start_index=40027, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=The%20assignment%20of%20neurofibromin%20as,interacting%20proteins%20%28Fig.%C2%A02A%29%2C%20which')
120. AnnotationURLCitation(end_index=40606, start_index=40418, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=activity%2C%20attention%20has%20mainly%20focused,current%20understanding%20of%20neurofibromin%20function')
121. AnnotationURLCitation(end_index=40788, start_index=40607, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=The%20assignment%20of%20neurofibromin%20as,interacting%20proteins%20%28Fig.%C2%A02A%29%2C%20which')
122. AnnotationURLCitation(end_index=41164, start_index=41013, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=As%20we%20learn%20more%20about,proteins%20or%20pathways%20will%20be')
123. AnnotationURLCitation(end_index=41576, start_index=41397, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Moreover%2C%20at%20least%20four%20alternatively,expression%20is%20exclusively%20restricted%20to')
124. AnnotationURLCitation(end_index=41752, start_index=41577, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=alternatively%20spliced%20exon%2011alt12%20,granular%20structures%2C%20supporting%20a%20non')
125. AnnotationURLCitation(end_index=42166, start_index=42049, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=deficits%20in%20mice%20,2%29%20is')
126. AnnotationURLCitation(end_index=42329, start_index=42167, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Finally%2C%20an%20isoform%20with%20a,specific%20analyses%20of%20its%20function')
127. AnnotationURLCitation(end_index=42997, start_index=42840, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=The%20CTD%20contains%20a%20functional,GAP%20activity%20of%20neurofibromin%20%5B56%2C57')
128. AnnotationURLCitation(end_index=43155, start_index=42998, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=The%20cysteine%2Fserine,neurofibromin%2C%20and%20the%20highly%20probable')
129. AnnotationURLCitation(end_index=43508, start_index=43351, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=The%20CTD%20contains%20a%20functional,GAP%20activity%20of%20neurofibromin%20%5B56%2C57')
130. AnnotationURLCitation(end_index=43809, start_index=43673, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=serotonin%205,for%20the%20proper%20functioning%20of')
131. AnnotationURLCitation(end_index=44186, start_index=44078, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=match%20at%20L532%20addition%20to,PML')
132. AnnotationURLCitation(end_index=44515, start_index=44395, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=this%20protein,Some%20neurofibromin')
133. AnnotationURLCitation(end_index=44691, start_index=44516, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=cell%20surface%2C%20the%20cytoskeleton%20and,The%20diversity%20of%20protein%20associations')
134. AnnotationURLCitation(end_index=45472, start_index=45352, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=this%20protein,Some%20neurofibromin')
135. AnnotationURLCitation(end_index=45982, start_index=45831, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=As%20we%20learn%20more%20about,proteins%20or%20pathways%20will%20be')
136. AnnotationURLCitation(end_index=46318, start_index=46180, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=As%20we%20learn%20more%20about,MEK%20activity%2C%20the')
137. AnnotationURLCitation(end_index=46659, start_index=46521, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=As%20we%20learn%20more%20about,MEK%20activity%2C%20the')
138. AnnotationURLCitation(end_index=47122, start_index=46987, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=MPNST,studies%20that%20provide%20a%20comprehensive')
139. AnnotationURLCitation(end_index=47250, start_index=47123, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=topic,in%20NF1%2C%20and%20the%20importance')
140. AnnotationURLCitation(end_index=47870, start_index=47705, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=tibia%20bone%20defects%20and%20scoliosis,not%20known%20whether%20this%20proposed')
141. AnnotationURLCitation(end_index=48024, start_index=47871, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=neurofibromin%20function%2C%20implying%20a%20Ras,conjugation%20sites')
142. AnnotationURLCitation(end_index=48780, start_index=48620, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=structure%20neurofibromin%20revealed%20that%20it,GAP%20activity%20in%20vitro')
143. AnnotationURLCitation(end_index=48925, start_index=48781, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=%28Lupton%20et%20al,studies%20evolve%2C%20it%20will%20become')
144. AnnotationURLCitation(end_index=49506, start_index=49331, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=addition%2C%20it%20was%20reported%20that,pathways%20and%20possible%20therapeutic%20targets')
145. AnnotationURLCitation(end_index=49983, start_index=49845, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=As%20we%20learn%20more%20about,MEK%20activity%2C%20the')
146. AnnotationURLCitation(end_index=50142, start_index=49984, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=clinical%20manifestations%20of%20NF1%20in,is%20likely%20to%20improve%20our')
147. AnnotationURLCitation(end_index=50477, start_index=50352, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromatosis%20type%201%20,caf%C3%A9')
148. AnnotationURLCitation(end_index=50720, start_index=50571, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=,15%5D.%20Symptoms')
149. AnnotationURLCitation(end_index=51120, start_index=50985, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=been%20shown%20to%20be%20an,changes%2C%20as%20well%20as%20tissue')
150. AnnotationURLCitation(end_index=51592, start_index=51443, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=,15%5D.%20Symptoms')
151. AnnotationURLCitation(end_index=51944, start_index=51733, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=NF1%20results%20from%20mutations%20in,Clinical%20manifestations%20of%20NF1%20are')
152. AnnotationURLCitation(end_index=52305, start_index=52147, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=Neurofibromin%20can%20be%20found%20in,22%7D.%20Other%20symptoms%20include')
153. AnnotationURLCitation(end_index=52657, start_index=52517, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=reported,expression%20is%20exclusively%20restricted%20to')
154. AnnotationURLCitation(end_index=52907, start_index=52787, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=reported,147%20Geist%20and%20Gutmann')
155. AnnotationURLCitation(end_index=53436, start_index=53257, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Moreover%2C%20at%20least%20four%20alternatively,expression%20is%20exclusively%20restricted%20to')
156. AnnotationURLCitation(end_index=53601, start_index=53437, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=This%20isoform%20is%20intriguing%2C%20as,exon%2021%20was%20recently%20identified')
157. AnnotationURLCitation(end_index=54219, start_index=54008, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=Ras%20at%20the%20plasma%20membrane%2C,Clinical%20manifestations%20of%20NF1%20are')
158. AnnotationURLCitation(end_index=54378, start_index=54220, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=Neurofibromin%20can%20be%20found%20in,22%7D.%20Other%20symptoms%20include')
159. AnnotationURLCitation(end_index=55111, start_index=54910, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=contains%20a%20central%20Ras,NF1%20mutations%2C%20and%20some%20exhibit')
160. AnnotationURLCitation(end_index=55521, start_index=55320, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=contains%20a%20central%20Ras,NF1%20mutations%2C%20and%20some%20exhibit')
161. AnnotationURLCitation(end_index=55775, start_index=55622, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Neurofibromin%20requires%20SPRED1%20to%20localize,2018%20%3B%20%20134')
162. AnnotationURLCitation(end_index=56151, start_index=55997, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=Neurofibromin%20was%20long%20thought%20to,was%20an%20intriguing%20observation%20and')
163. AnnotationURLCitation(end_index=56275, start_index=56152, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=activity%20,in%20which%20the%20underlined%20residues')
164. AnnotationURLCitation(end_index=56887, start_index=56744, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP')
165. AnnotationURLCitation(end_index=57204, start_index=57061, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP')
166. AnnotationURLCitation(end_index=57449, start_index=57309, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=individuals%20with%20NF1%2C%20loss,oncogene%20regulation')
167. AnnotationURLCitation(end_index=57737, start_index=57597, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=individuals%20with%20NF1%2C%20loss,oncogene%20regulation')
168. AnnotationURLCitation(end_index=57901, start_index=57738, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=residues%29%5E%7B63%20%7D.%20The%20Ras,this%20domain%20with%20Ras%2C%20whereas')
169. AnnotationURLCitation(end_index=58224, start_index=58084, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=individuals%20with%20NF1%2C%20loss,oncogene%20regulation')
170. AnnotationURLCitation(end_index=58793, start_index=58689, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=NF1,Rac1%20signaling')
171. AnnotationURLCitation(end_index=58938, start_index=58794, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=increased%20RAS%20activity%20and%20elevated,Rac1%20signaling')
172. AnnotationURLCitation(end_index=59297, start_index=59193, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=NF1,Rac1%20signaling')
173. AnnotationURLCitation(end_index=59442, start_index=59298, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=increased%20RAS%20activity%20and%20elevated,Rac1%20signaling')
174. AnnotationURLCitation(end_index=59898, start_index=59754, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=increased%20RAS%20activity%20and%20elevated,Rac1%20signaling')
175. AnnotationURLCitation(end_index=60358, start_index=60173, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=peripheral%20nerve%20sheaths%2C%20called%20neurofibromas,and%20progress%20to%20malignant%20peripheral')
176. AnnotationURLCitation(end_index=60830, start_index=60648, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=manifestations%20in%20any%20given%20individual,assessment%20and%20proactive%20medical%20management')
177. AnnotationURLCitation(end_index=60964, start_index=60831, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=function,been%20identified%20in%20human%20tumors')
178. AnnotationURLCitation(end_index=61314, start_index=61113, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=cognitive%20impairments%2C%20and%20behavioral%20alterations,26%2C%2029')
179. AnnotationURLCitation(end_index=61634, start_index=61415, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=symptoms%20including%20pigmentation%20defects%2C%20skeletal,of%20children%20experiencing')
180. AnnotationURLCitation(end_index=62206, start_index=61989, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=of%20dendritic%20spines%20due%20to,replicate%20cognitive%20and%20behavioral%20deficits')
181. AnnotationURLCitation(end_index=62435, start_index=62207, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=observed%20in%20NF1%20patients%2C%20manifesting,ameliorates%20learning%20deficits%20and%20rescues')
182. AnnotationURLCitation(end_index=63047, start_index=62871, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=Neurofibromin%20is%20ubiquitously%20expressed%20with,is%20largely%20unknown%2C%20there%20is')
183. AnnotationURLCitation(end_index=63370, start_index=63212, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=develop%20other%20symptoms%2C%20such%20as,large%20multifunctional%20protein%20that%20is')
184. AnnotationURLCitation(end_index=63741, start_index=63609, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=with%20one%20mutated%20%28non,2001%20%3B%20%2020')
185. AnnotationURLCitation(end_index=64118, start_index=63930, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=pathways%2C%20such%20as%20cAMP%2FPKA%2C%20are,68%5D.%20In')
186. AnnotationURLCitation(end_index=64475, start_index=64268, title='Unraveling neuronal and metabolic alterations in neurofibromatosis type 1 | Journal of Neurodevelopmental Disorders | Full Text', type='url_citation', url='https://jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-024-09565-6#:~:text=of%20cyclic%20adenosine%20monophosphate%20,are%20implicated%20in%20many%20of')
187. AnnotationURLCitation(end_index=65021, start_index=64878, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=Exons%2027,NF1%20mutations%20decrease%20neurofibromin%20GAP')
188. AnnotationURLCitation(end_index=65168, start_index=65022, title='RAS and beyond: the many faces of the neurofibromatosis type 1 protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8891636/#:~:text=regulate%20the%20activity%20of%20all,deficient%20mouse%20cells')
189. AnnotationURLCitation(end_index=65473, start_index=65326, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=neurofibromatosis%20type%201%20%28NF1%29,studied%2C%20showing%20it%20to%20be')
190. AnnotationURLCitation(end_index=65652, start_index=65474, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=fundamental%20cellular%20processes%2C%20such%20as,literature%20on%20neurofibromin%20structure%2C%20function')
191. AnnotationURLCitation(end_index=65915, start_index=65763, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=electron%20microscopy%20%28cryo,The%20transition%20between%20closed')
192. AnnotationURLCitation(end_index=66085, start_index=65916, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=homodimer%20is%20characterized%20by%20a,two%20conformational%20states%3A%20an%20auto')
193. AnnotationURLCitation(end_index=66340, start_index=66204, title='Neurofibromin Structure, Functions and Regulation', type='url_citation', url='https://www.mdpi.com/2073-4409/9/11/2365/htm#:~:text=match%20at%20L559%20enables%20its,Ras%2C%20allowing%20a%20precise')
194. AnnotationURLCitation(end_index=66636, start_index=66513, title='The therapeutic potential of neurofibromin signaling pathways and binding partners - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10119308/#:~:text=match%20at%20L1675%20,Google%20Scholar')
195. AnnotationURLCitation(end_index=66821, start_index=66711, title='Pan-RAS inhibitor RMC-7977 is efficacious in treating NF1-related tumors | Neuro-Oncology Advances | Oxford Academic', type='url_citation', url='https://academic.oup.com/noa/article-abstract/7/1/vdaf065/8090527#:~:text=,7977%20is%20a')